Last reviewed · How we verify
Voriconazole high dose
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.
At a glance
| Generic name | Voriconazole high dose |
|---|---|
| Also known as | Vfend |
| Sponsor | Manjunath Prakash Pai |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Voriconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to fungal cell membrane instability and cell death. High-dose regimens are used to achieve adequate tissue penetration, particularly in the central nervous system and for treatment of invasive infections.
Approved indications
- Invasive aspergillosis
- Candidemia and other Candida infections
- Esophageal candidiasis
- Cryptococcal meningitis
- Scedosporium and Fusarium infections
Common side effects
- Visual disturbances (blurred vision, photopsia)
- Hepatotoxicity (elevated transaminases)
- Rash
- Photosensitivity
- Hallucinations
- Hypokalemia
- Nausea and vomiting
Key clinical trials
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (PHASE1, PHASE2)
- Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voriconazole high dose CI brief — competitive landscape report
- Voriconazole high dose updates RSS · CI watch RSS
- Manjunath Prakash Pai portfolio CI